Paul Roellig, CEO of BulletinNEWS explains how restrictions on advertising and social media by the FDA could impact the medical publishing business and cut off valuable sources of information for healthcare professionals.
Paul Roellig of BulletinNEWS on the FDA and Publishing
November 20th, 2009 · No Comments · News
Tags: #fdasm·advertising·communication·Communities·Compliance·Conferences·digital strategy·Digital Tools·drug safety·Education·FDA·Legal Issues·marketing·media·Patients·Pharma·Pharmaceutical industry·social media·Thought Leaders·Trends
No Comments so far ↓
There are no comments yet...Kick things off by filling out the form below.